The Supreme Court refused to hear 2 cases arising from efforts by states to bar Planned Parenthood clinics from the Medicaid program; the NIH will spend up to $20 million over 2 years to find and develop alternatives to using fetal tissue in research projects; whether or not the United States needs another opioid painkiller on the market has been widely debated since the FDA approved Dsuvia last month.
The Supreme Court refused to hear 2 cases arising from efforts by states to bar Planned Parenthood clinics from the Medicaid program, The New York Times reported. In letting stand the decisions allowing patients to challenge state funding determinations, the Supreme Court effectively sided with Planned Parenthood. That drew criticism from the court’s 3 most conservative justices: Justices Clarence Thomas, Samuel A. Alito Jr., and Neil M. Gorsuch. The other 2 conservatives—Chief Justice John G. Roberts Jr. and Justice Brett M. Kavanaugh—declined to join, indicating a desire to steer clear of controversial topics.
The NIH will spend up to $20 million over 2 years to find and develop alternatives to using fetal tissue in research projects, The Hill reported, after facing pressure from anti-abortion groups. NIH said it will solicit applications soon to "develop" or "further refine" human tissue models that can model human biology. In addition, HHS is still conducting a review of more than $100 million in federal funding of fetal tissue research projects. Many biologists argue fetal tissue is critical to improving biomedical research, especially in HIV applications.
Whether or not the United States needs another opioid painkiller on the market has been widely debated since the FDA approved Dsuvia last month. STAT analyzed whether or not the drug, a fast-acting tablet version of a decades-old intravenous painkiller that is up to 10 times more potent than the highly addictive fentanyl, lives up to its promises. The approval was championed by the military, which said the drug is needed in combat zones. While the drug could prove useful in some situations, the approval could be problematic, the report said.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More